Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acapatamab Combinations and Monotherapy in mCRPC
NCT04631601Phase 2Terminated
- Sponsor
- Amgen
- Start
- Jan 2021
- Primary completion
- Oct 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of acapatamab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Amgen. Started Jan 2021; status: terminated.
02
Drugs
acapatamab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04631601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631601.